iNO administered

Phase 1Small molecule

TThe Cleveland Clinic

iNO administered is one of 41 small molecule programs targeting Congenital Heart Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Congenital Heart DiseaseActive, not recruiting

Congenital Heart DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Congenital Heart Disease

#DrugCompanyPhaseTrials

Tracleer

Johnson & Johnson

Approved

1 2

Opsumit

Theo-Dur

Intropin

Remodulin

Pepcid

1 7

Feraheme

AAzurity Pharmaceuticals

Approved

1 8

Jardiance

Boehringer Ingelheim

Approved

1 9

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 10

Decadron

AAspen Global Incorporated

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Congenital Heart Disease1 trial

Pilot Study of Inhaled Nitric Oxide to Treat Pulmonary Insufficiency in Congenital Heart Disease

Terminated·TThe Cleveland Clinic·Phase 1·NCT00543933·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for iNO administered. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iNO administered compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iNO administered. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Cleveland Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: TThe Cleveland Clinic

iNO administered

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Congenital Heart Disease1 trial

References

Drug Info

Quick Facts

Related News